Document is current
Any future updates will be listed below
-
Authors
Cross, William
Lyskjær, Iben
Davies, Christopher
Bunkum, Abigail
Rocha, Ana Maia
Lesluyes, Tom
Amary, Fernanda
Tirabosco, Roberto
Naceur-Lombardelli, Cristina
,
Hessey, Sonya
Shiu, Kai-Keen
Bridgewater, John
Hochhauser, Daniel
Forster, Martin
Lee, Siow-Ming
Ahmad, Tanya
Papadatos-Pastos, Dionysis
Janes, Sam
Enfield, Katey
McGranahan, Nicholas
Huebner, Ariana
Quezada, Sergio
Beck, Stephan
Parker, Peter
Enver, Tariq
Hynds, Robert E.
Pearce, David R.
Falzon, Mary
Proctor, Ian
Sinclair, Ron
Lok, Chi-wah
Rhodes, Zoe
Moore, David
Marafioti, Teresa
Mitchison, Miriam
Ellery, Peter
Sivakumar, Monica
Linch, Mark
Brandner, Sebastian
Rowan, Andrew
Hiley, Crispin
Veeriah, Selvaraju
Shaw, Heather
Attard, Gert
Toncheva, Antonia
Prymas, Paulina
Watkins, Thomas B. K.
Bailey, Chris
Martinez Ruiz, Carlos
Litchfield, Kevin
Al-Bakir, Maise
Kanu, Nnenna
Ward, Sophia
Lim, Emilia
Reading, James
Chain, Benny
Trujillo Alba, Blanca
Watkins, Tom
Akay, Melek
Biswas, Dhruva
Pich, Oriol
Dietzen, Michelle
Puttick, Clare
Colliver, Emma
Magness, Alistair
Angelova, Mihaela
Black, James
Lucas, Olivia
Hill, William
Liu, Wing-Kin
Frankell, Alexander
Magno, Neil
Athanasopoulou, Foteini
Salgado, Roberto
Lee, Claudia
Grigoriadis, Kristiana
Al-Sawaf, Othman
Karasaki, Takahiro
Noorani, Imran
Benafif, Sarah
Barbe, Vittorio
Bola, Supreet
Vainauskas, Osvaldas
Wingate, Anna
Wetterskog, Daniel
Hasan, Mahedi
Lise, Stefano
Leone, GianMarco
Jayaram, Anuradha
Alifrangis, Constantine
McGovern, Ursula
Thol, Kerstin
Gamble, Samuel
Ung, Seng Kuong
Sahwangarrom, Teerapon
Peinador Marin, Claudia
Wong, Sophia
Pawlik, Piotr
Lam, Jie Min
Richard, Corentin
Vendramin, Roberto
Dijkstra, Krijn
Rane, Jayant
Nicod, Jerome
Zaidi, Rija
Gishen, Faye
Tookman, Adrian
Stone, Paddy
Stirling, Caroline
Turajlic, Samra
Larkin, James
Pickering, Lisa
Furness, Andrew
Young, Kate
Drake, Will
Edmonds, Kim
Hunter, Nikki
Mangwende, Mary
Pearce, Karla
Au, Lauren Lewis
Spain, Lavinia
Shepherd, Scott
Yan, Haixi
Shum, Ben
Tippu, Zayd
Hanley, Brian
Spencer, Charlotte
Emmerich, Max
Gerard, Camille
Schmitt, Andreas Michael
Del Rosario, Lyra
Carlyle, Eleanor
Lewis, Charlotte
Holt, Lucy
Lucanas, Analyn
O’Flaherty, Molly
Hazell, Steve
Mudhar, Hardeep
Messiou, Christina
Latifoltojar, Arash
Fendler, Annika
Byrne, Fiona
Pallinkonda, Husayn
Lobon, Irene
Coulton, Alex
Cattin, Anne Laure
Deng, Daqi
Feng, Geoffrey Hugang
Rowan, Andew
Yousaf, Nadia
Popat, Sanjay
Curtis, Olivia
Milner-Watts, Charlotte
Stamp, Gordon
Nye, Emma
Murra, Aida
Korteweg, Justine
Kelly, Denise
Terry, Lauren
Biano, Jennifer
Peat, Kema
Kelly, Kayleigh
Hill, Peter
Josephs, Debra
Irshad, Sheeba
Spicer, James
Mahadeva, Ula
Green, Anna
Stewart, Ruby
Wright, Natasha
Pulman, Georgina
Mitu, Ruxandra
Phillips-Boyd, Sherene
Enting, Deborah
Rudman, Sarah
Ghosh, Sharmistha
Karapagniotou, Lena
Pintus, Elias
Tutt, Andrew
Howlett, Sarah
Brenton, James
Caldas, Carlos
Fitzgerald, Rebecca
Jimenez-Linan, Merche
Provenzano, Elena
Cluroe, Alison
Paterson, Anna
Aitken, Sarah
Allinson, Kieren
Stewart, Grant
McDermott, Ultan
Beddowes, Emma
Maughan, Tim
Ansorge, Olaf
Campbell, Peter
Roxburgh, Patricia
Fraser, Sioban
Blyth, Kevin
Le Quesne, John
Krebs, Matthew
Blackhall, Fiona
Summers, Yvonne
Oliveira, Pedro
Ortega-Franco, Ana
Dive, Caroline
Gomes, Fabio
Carter, Mat
Dransfield, Jo
Thomas, Anne
Fennell, Dean
Shaw, Jacqui
Naidu, Babu
Baijal, Shobhit
Tanchel, Bruce
Langman, Gerald
Robinson, Andrew
Collard, Martin
Cockcroft, Peter
Ferris, Charlotte
Bancroft, Hollie
Kerr, Amy
Middleton, Gary
Webb, Joanne
Kadiri, Salma
Colloby, Peter
Olisemeke, Bernard
Wilson, Rodelaine
Tomlinson, Ian
Jogai, Sanjay
Holden, Samantha
Fernandes, Tania
McNeish, Iain
Hampton, Blanche
McKenzie, Mairead
Hackshaw, Allan
Sharp, Abby
Chan, Kitty
Farrelly, Laura
Bridger, Hayley
Leslie, Rachel
Jamal-Hanjani, Mariam
Swanton, Charles
Pillay, Nischalan
Zaccaria, Simone
Flanagan, Adrienne M.
Van Loo, Peter
-
Funding
Funding for this research was provided by:
Bone Cancer Research Trust (BCRT 6820)
Lundbeck Foundation (R303-2018-3018)
Cancer Research UK (CC2008, CC2041, RCCCDF-Nov21\100005)
Wellcome Trust (CC2008, CC2041)
Medical Research Council (CC2008, CC2041)
Sarcoma UK (SUKG01.2018)
Cancer Prevention and Research Institute of Texas (RR210006)
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 24 September 2025
First Online: 26 November 2025
Declarations
:
: Use of the samples for this research project (project no: EC17.14) was granted by the UCL/UCLH Biobank Ethics Committee, a committee that is approved by the National Research Ethics Committee (Integrated Research Application System (IRAS) project identifier: 272816). The samples included in the project were held at the Royal National Orthopaedic Hospital (RNOH), a UCL satellite licensed Human Tissue Authority-approved premises (Licensing no. 12055).
: M.J-H. has consulted for, and is a member of, the Achilles Therapeutics Scientific Advisory Board and Steering Committee, has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, and holds a patent PCT/US2017/028013 relating to methods for lung cancer detection. C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx Inc—collaboration in minimal residual disease sequencing technologies), and Ono Pharmaceutical. He is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s Scientific Advisory Board. He receives consultant fees from Achilles Therapeutics (also SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre – Shanghai, Metabomed (until July 2022), and the Sarah Cannon Research Institute C.S has received honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina, and Roche-Ventana. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. Patents: C.S. holds patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892).
